MarketCap
Facebook
X
TelegramHeat Biologics, Inc. Total Assets 2011-2025 | HTBX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Heat Biologics, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 124 M | 26 M | 37.8 M | 20.2 M | 8.9 M | 13.2 M | 15.9 M | 23 M | 148 K | 182 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 124 M | 148 K | 26.9 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Pharming Group N.V.
PHAR
|
215 M | $ 17.91 | -1.0 % | $ 7.59 B |  Niderland |
 |
InflaRx N.V.
IFRX
|
76 M | $ 1.09 | -4.82 % | $ 152 M | Germany |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B |  USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 1.15 | -1.71 % | $ 6.27 M |  China |
 |
Arbutus Biopharma Corporation
ABUS
|
144 M | $ 4.78 | -0.31 % | $ 793 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
220 M | $ 3.03 | -0.49 % | $ 234 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
1.18 B | $ 209.39 | -1.61 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
15.6 M | $ 0.6 | -35.8 % | $ 166 K | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.66 | -1.49 % | $ 424 M | Britain |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.12 | 0.81 % | $ 7.51 B |  Australia |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
BioVie
BIVI
|
21.6 M | $ 1.2 | -5.51 % | $ 1.77 M | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
23.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 0.22 | 24.46 % | $ 479 M |  Israel |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
283 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
22.5 B | $ 94.72 | -0.33 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.58 B | $ 27.09 | 1.04 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
5.92 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | USA |
 |
Anika Therapeutics
ANIK
|
271 M | $ 9.6 | 1.27 % | $ 141 M | USA |
 |
bluebird bio
BLUE
|
619 M | - | - | $ 546 M | USA |
 |
Zai Lab Limited
ZLAB
|
1.19 B | $ 18.4 | -0.97 % | $ 18.2 B | China |
 |
Catalyst Biosciences
CBIO
|
117 M | $ 12.33 | -0.29 % | $ 812 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
4.47 B | $ 584.81 | -1.07 % | $ 44.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.44 | -3.56 % | $ 15.3 M | USA |
 |
AstraZeneca PLC
AZN
|
104 B | $ 92.79 | 0.37 % | $ 96.9 B | Britain |
 |
ChromaDex Corporation
CDXC
|
68.3 M | - | -0.88 % | $ 598 M | USA |
 |
Certara
CERT
|
1.58 B | $ 8.9 | -0.17 % | $ 1.43 B | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |